XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") XRTXXRTXANUA)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a summary of Company's…#calgary #alberta #xortxtherapeuticsinc #xortx #allendavidoff #autosomaldominant #fda #usfda #xorlo #boardofdirectors (Source: Reuters: Health)
Source: Reuters: Health - March 19, 2024 Category: Consumer Health News Source Type: news
National Institute on Drug Abuse Clinical Trials Network meeting report: managing patients exposed to xylazine-adulterated opioids in emergency, hospital and addiction care settings - Perrone J, Haroz R, D'Orazio J, Gianotti G, Love J, Salzman M, Lowenstein M, Thakrar A, Klipp S, Rae L, Reed MK, Sisco E, Wightman R, Nelson LS.
Used as a veterinary sedative and not approved for human use, xylazine has been increasingly linked with opioid overdose deaths in the United States. A growing number of people have been exposed to xylazine in the illicit opioid supply (especially fentanyl... (Source: SafetyLit)
Source: SafetyLit - March 19, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Electronic Nudges to Get the Flu Shot Fall Short for Vax Rates, Outcomes
(MedPage Today) -- Electronic nudges sent to patients failed to increase influenza vaccine uptake in one randomized clinical trial, while another trial found that slight increases in vaccination rates from letters emailed to patients failed to... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - March 19, 2024 Category: Infectious Diseases Source Type: news
IGH Naturals begins clinical trial for product to ease chemotherapy side effects
Rocklin supplement company IGH Naturals Inc. has won approval to conduct a clinical study on the effectiveness of its food product to ease harsh side effects of chemotherapy in cancer patients. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 16, 2024 Category: Biotechnology Authors: Mark Anderson Source Type: news
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical trial program also showed reduction in sinus inflammation and in acute exacerbations, which…#reopen #xhance #yardley #optn #fda #sciatica #rickchandra #rolandroneavey #vanderbiltuniversity #ramymahmoud (Source: Reuters: Health)
Source: Reuters: Health - March 15, 2024 Category: Consumer Health News Source Type: news
Study Explores Safety of Removing Inoperable Pancreatic Tumors
A clinical trial will examine if chemotherapy followed by a novel surgical procedure can improve outcomes for patients with pancreatic tumors previously considered inoperable (Source: Disabled World)
Source: Disabled World - March 15, 2024 Category: Disability Tags: Pancreatic Cancer Source Type: news
Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study) - Akechi T, Furukawa TA, Noma H, Iwata H, Toyama T, Higaki K, Matsuoka H, Zenda S, Iwatani T, Akahane K, Inoue A, Sagara Y, Uchida M, Imai F, Momino K, Imaizumi G, Yamaguchi T, Mashiko T, Miyaji T, Horikoshi M, Sakurai N, Onishi T, Kanemitsu Y, Murata T, Wanifuchi-Endo Y, Kuroda H, Nishikawa R, Miyashita M, Abe M, Uchitomi Y.
AIM: Patients with cancer experience various forms of psychological distress, including depressive symptoms, which can impact quality of life, elevate morbidity risk, and increase medical costs. Psychotherapy and pharmacotherapy are effective for reducing ... (Source: SafetyLit)
Source: SafetyLit - March 15, 2024 Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news
Traumatic brain injury and stem cell treatments: a review of recent 10 years clinical trials - Saboori M, Riazi A, Taji M, Yadegarfar G.
Traumatic brain injury (TBI) is damage to the brain by an external physical force. It may result in cognitive and physical dysfunction. It is one of the main causes of disability and death all around the world. In 2016, the worldwide incidence of acute TBI... (Source: SafetyLit)
Source: SafetyLit - March 15, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Bright light therapy for major depressive disorder in adolescent outpatients: a preliminary study - Ballard R, Parkhurst JT, Gadek LK, Julian KM, Yang A, Pasetes LN, Goel N, Sit DK.
BACKGROUND: Bright light therapy (BLT) has not been well-studied in adolescents with major depressive disorder, particularly in outpatient settings. METHODS: We conducted an 8-week clinical trial of BLT in adolescents recruited from a primary care ... (Source: SafetyLit)
Source: SafetyLit - March 15, 2024 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Trially wants to transform $22.6B clinical trial industry
Trially, a health tech startup in Kansas City, wants to modernize the clinical trial recruitment process with an artificial intelligence platform. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 14, 2024 Category: Pharmaceuticals Authors: Grace Mayer Source Type: news
England's NHS Clinics No Longer Offering Puberty Blockers to Trans Youth
(MedPage Today) -- England's National Health Service (NHS) will no longer offer puberty-blocking medications to youths under 18 in its clinics, unless they are enrolled in clinical trials planned for the end of the year.
"Puberty suppressing hormones... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 14, 2024 Category: Psychiatry Source Type: news
Trialbee's Jamie Goldfarb to Lead Discussion on Defining Success and Enhancing Collaboration in Clinical Trials at Patients as Partners in Clinical Research Conference
2023 Linnea Olson Patient Advocate of the Year award winner will also serve as an advocacy mentor at the conference (March 20-22, Philadelphia, PA) CHAPEL HILL, N.C. and MALMÖ, Sweden, March 14, 2024 /PRNewswire-PRWeb/ -- Trialbee, the global leader in technology-driven patient... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 14, 2024 Category: Pharmaceuticals Source Type: news
£ 2.2 million for clinical trial to improve general practice response to men and children affected by domestic abuse
A new clinical trial of a general practice programme to improve the identification and referral of men and children affected by domestic abuse begins in May thanks to a £ 2.2 million National Institute for Health and Care Research (NIHR) award to University of Bristol researchers, in partnership with Oxford University and the social enterprise IRISi. (Source: University of Bristol news)
Source: University of Bristol news - March 14, 2024 Category: Universities & Medical Training Tags: Health, Grants and Awards, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Population Health Sciences, Faculty of Health Sciences, Bristol Medical School, Institutes, Institutes, Bristol Population Health Science Institute Source Type: news
Clinical Data Analytics Solutions Market Projected to Reach USD 7.5 Billion by 2030, Driven by AI Integration and Increase in Clinical Trials
DUBLIN, March 13, 2024 /PRNewswire/ -- The "Clinical Data Analytics Solutions Market Size, Share & Trends Analysis Report By Deployment (Cloud-based, On-premise), By Application (Clinical Decision Support, Clinical Trials, Regulatory Compliance), By Region, And Segment Forecasts, 2024 -... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 14, 2024 Category: Pharmaceuticals Tags: MRR Source Type: news
Pulsenmore is expanding the application of its home ultrasound solution for pregnant women: a clinical trial with Michigan Medicine will focus on the remote assessment of the fetal biophysical profile
RAMAT GAN, Israel, March 13, 2024 /PRNewswire/ -- Pulsenmore (TASE:PULS), the world leader in self-scan ultrasound technology for at-home use and remote clinical diagnosis, announces its new clinical study collaboration with Michigan Medicine. The study will examine the ability to conduct... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 13, 2024 Category: Pharmaceuticals Tags: TRI PDT Source Type: news